Status:
COMPLETED
rhGH Therapy on Hepatic Drug Metabolism
Lead Sponsor:
University of Louisville
Collaborating Sponsors:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Conditions:
Growth Hormone Deficiency, Dwarfism
Eligibility:
All Genders
4-14 years
Brief Summary
The purpose of the study is to understand the effect of rhGH therapy on hepatic drug metabolism in children with idiopathic growth hormone deficiency.
Detailed Description
Growth Hormone (GH) deficiency is a prominent cause of short stature, affecting approximately 14,000 children in the US. Although a single study has demonstrated reduces CYP1A2 activity following Gh r...
Eligibility Criteria
Inclusion
- Children ages 4 to 14 years with a height less than the 5th percentile for age and sex or having a decelerated across two major percentiles (5th, 10th, 25th, 50th, 90th, and 95th) on standard pediatric growth curves, poor growth velocity (less than 5 centimeters/year), radiographic evidence of delayed bone age (i.e. greater than 1 SD below the mean for chronological age) and a documented diagnosis of idiopathic growth hormone deficiency \[as determined by failure to raise serum GH concentrations 10 microgram/Liter following provocative testing with two growth hormone secretagogues(e.g. insulin, arginine, or clonidine)\].
- All subjects will be prepubertal, as determined by Tanner staging.
Exclusion
- Children receiving medications known to induce or inhibit hepatic CYP1A2, NAT-2, XO, CYP2D6 or CYP3A4 activity.
- Subjects with a history of smoking (including exposure to second hand smoke \> 8 hours per day) or illicit drug use.
- Subjects with a history of hepatic, renal, cardiac or thyroid disorders. Presence of hepatic, renal, cardiac or thyroid disease will be established based on clinical history and results of recent laboratory tests conducted as part of the routine medical evaluation of children who are being considered for rhGH therapy.
- Children experiencing fever or acute viral illness
- Children who have a history of a hypersensitivity reaction to dextromethorphan or caffeine
- Children who have received prior treatment with rhGH
- Children who are receiving corticosteroids or thyroid hormone
Key Trial Info
Start Date :
June 1 2001
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00458991
Start Date
June 1 2001
End Date
September 1 2008
Last Update
April 27 2017
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California at San Diego
San Diego, California, United States, 92103
2
Kosair Charities Pediatric Clinical Research Unit
Louisville, Kentucky, United States, 40202
3
Children's Mercy Hospital and Clinics
Kansas City, Missouri, United States, 64108
4
Rainbow Babies and Children's Hospital
Cleveland, Ohio, United States, 44106-6010